Vladimir Janković

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang et al. · The Lancet Oncology · 2020 · 457 citations · Full text

Single-arm Trial, Medicine, Pathology +5

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Alexander Stratigos, Aleksandar Sekulić, Ketty Peris et al. · The Lancet Oncology · 2021 · 266 citations · Full text

Medicine, Hedgehog Inhibitor Therapy, Dermatology +5

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 207 citations · Full text

Surgical Oncology, Hepatology, Resectable Hepatocellular Carcinoma +10

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Danny Rischin, Michael R. Migden, Annette M. Lim et al. · Journal for ImmunoTherapy of Cancer · 2020 · 169 citations · Full text

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 ⁺ T cell dysfunction and maintain memory phenotype

Bei Wang, Wen Zhang, Vladimir Janković et al. · Science Immunology · 2018 · 161 citations